Literature DB >> 17429564

Telomerase activity in tumor and remnant liver as predictor of recurrence and survival in hepatocellular carcinoma after resection.

Yan-Shen Shan1, Yu-Hsiang Hsieh, Pin-Wen Lin.   

Abstract

BACKGROUND AND AIM: Results after curative liver resection in hepatocellular carcinoma are unsatisfactory with regard to high postoperative intrahepatic recurrence and liver failure. This study evaluates telomerase activity in liver with and without tumor as a predictor of recurrence and survival.
MATERIALS AND METHODS: Liver tissue with and without tumor from 53 hepatocellular carcinoma patients receiving curative resection during the period of 1998-2000 was used for detecting telomerase activity by PCR-ELISA. Clinicopathological data were compared to identify predictors of recurrence and survival.
RESULTS: Telomerase activity was detected in 98% of liver tissue with tumor and 70% liver tissue without. Telomerase activity in cancerous liver correlated significantly with HCV infection (P = 0.012) and cirrhotic change in liver parenchyma (P = 0.006). Telomerase activity in non-cancerous liver correlated with high serum AFP level (P = 0.002). The telomerase activity of liver tissue with and without tumor is significant higher in patients with recurrence than in those without recurrence, 413.7 +/- 100.5 versus 110.8 +/- 32.7, P = 0.006, and 34.7 +/- 14.2 versus 4.2 +/- 1.4, P = 0.039. Recurrence could be predicted by abnormally high tumor telomerase activity (P = 0.026) or by advanced TNM stage (P = 0.001). TNM stage or high serum ALT level could predict multinodular intrahepatic recurrence (P = 0.028 and P = 0.030). High serum AFP combined with high telomerase activity in liver without tumor had a significant ability to predict poor survival (OR: 11.19, CI: 1.95-64.12, P = 0.007).
CONCLUSION: Tumor telomerase is an independent predictor of recurrence. Simultaneous high remnant liver telomerase and high serum AFP is a strong negative predictor of survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17429564     DOI: 10.1007/s00268-006-0783-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  30 in total

1.  Telomeres and telomerase.

Authors:  M A Blasco; S M Gasser; J Lingner
Journal:  Genes Dev       Date:  1999-09-15       Impact factor: 11.361

2.  Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy.

Authors:  T Kobayashi; K Kubota; T Takayama; M Makuuchi
Journal:  Am J Surg       Date:  2001-03       Impact factor: 2.565

3.  Quantitation of telomerase activity in hepatocellular carcinoma: a possible aid for a prediction of recurrent diseases in the remnant liver.

Authors:  T Suda; O Isokawa; Y Aoyagi; M Nomoto; K Tsukada; T Shimizu; Y Suzuki; A Naito; H Igarashi; M Yanagi; T Takahashi; H Asakura
Journal:  Hepatology       Date:  1998-02       Impact factor: 17.425

4.  Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis.

Authors:  J Belghiti; Y Panis; O Farges; J P Benhamou; F Fekete
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

5.  Telomerase activity in hepatocellular carcinoma as a predictor of postoperative recurrence.

Authors:  K Ohta; T Kanamaru; Y Morita; Y Hayashi; H Ito; M Yamamoto
Journal:  J Gastroenterol       Date:  1997-12       Impact factor: 7.527

6.  Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study.

Authors:  Ana Graciela Puebla-Mora; Alfonso Heras; Ana María Cano-Valdez; Hugo Domínguez-Malagón
Journal:  Ann Diagn Pathol       Date:  2006-08       Impact factor: 2.090

Review 7.  Treatment of small hepatocellular carcinomas.

Authors:  G M Dusheiko; K E Hobbs; R Dick; A K Burroughs
Journal:  Lancet       Date:  1992-08-01       Impact factor: 79.321

8.  Telomerase activity in hepatocellular carcinoma and adjacent liver tissues.

Authors:  K Kishimoto; J Fujimoto; M Takeuchi; H Yamamoto; T Ueki; E Okamoto
Journal:  J Surg Oncol       Date:  1998-11       Impact factor: 3.454

9.  Telomerase is strongly activated in hepatocellular carcinoma but not in chronic hepatitis and cirrhosis.

Authors:  Y M Park; J Y Choi; B H Byun; C H Cho; H S Kim; B S Kim
Journal:  Exp Mol Med       Date:  1998-03-31       Impact factor: 8.718

10.  Quantitative analysis and in situ localization of human telomerase RNA in chronic liver disease and hepatocellular carcinoma.

Authors:  M Ogami; Y Ikura; S Nishiguchi; T Kuroki; M Ueda; M Sakurai
Journal:  Lab Invest       Date:  1999-01       Impact factor: 5.662

View more
  3 in total

1.  Hepatic resection for large hepatocellular carcinoma in the era of UCSF criteria.

Authors:  Spiros G Delis; Andreas Bakoyiannis; Nikos Tassopoulos; Kostas Athanassiou; Aristotelis Kechagias; Dimitrios Kelekis; Juan Madariaga; Christos Dervenis
Journal:  HPB (Oxford)       Date:  2009-11       Impact factor: 3.647

Review 2.  Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage.

Authors:  Adam Bartlett; Nigel Heaton
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

3.  Human telomerase activity, telomerase and telomeric template expression in hepatic stem cells and in livers from fetal and postnatal donors.

Authors:  Eva Schmelzer; Lola M Reid
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-10       Impact factor: 2.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.